Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded Access Study of Vemurafenib in Metastatic Melanoma
2015-004211-20Phase 2
- Sponsor
- Roche
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vemurafenib in melanoma, sponsored by Roche. Primary endpoint: Safety (Adverse Events).
02
Drugs
vemurafenib
03
Conditions
melanoma
Beyond the preview
Go deeper on 2015-004211-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004211-20.